Tag: ACC 2022
ACC.22: TAVI patients treated with edoxaban see fewer incidences of leaflet thrombosis compared to DAPT
Patients treated with edoxaban for six months after a transcatheter aortic valve implantation (T...
ACC.22: Analysis finds lower rate of structural valve deterioration with TAVI than SAVR at five years
Patients who received a transcatheter supra-annular self-expanding heart valve had less structural d...
ACC.22: NACMI registry finds reducing rates of death among STEMI patients with COVID-19
Latest results from the North American COVID-19 STEMI (NACMI) registry reported a 25% reduction ...
ACC.22: FFR-guided PCI non-inferior to IVUS for intermediate coronary stenosis
A head-to-head comparison of fractional flow reserve (FFR) and intravascular ultrasound (IVUS) guide...
ACC.22: Three-year data show “durable blood pressure reductions” through renal denervation
Long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial have been presented during ...
ACC.22: “Promising” one-year results for Pascal device in CLASP-TR trial
Patients with tricuspid regurgitation (TR) who received a Pascal transcatheter valve (Edwards Lifesc...
ACC.22: FAME 3 shows FFR-guided PCI leads to a faster recovery versus surgery
Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) leads to a fast...
Philips launches Ultrasound Workspace at ACC.22
Royal Philips is launching an echocardiography image analysis and reporting solution—Ultrasound Work...
